Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025220 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
A Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT00025220 is a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00025220, a Phase 2 study of Uterine Corpus Leiomyosarcoma and Recurrent Uterine Corpus Sarcoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Thalidomide
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2001-09 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00025220
The ClinicalTrials.gov registry entry for NCT00025220 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Uterine Corpus Leiomyosarcoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00025220 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00025220 about?
NCT00025220 is a clinical study titled "Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus". Phase II trial to study the effectiveness of thalidomide in treating patients who have recurrent or persistent cancer of the uterus. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
What is the current status of trial NCT00025220?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2001-09. Estimated completion is 2008-07.
What conditions does trial NCT00025220 study?
This clinical trial studies the following conditions: Uterine Corpus Leiomyosarcoma, Recurrent Uterine Corpus Sarcoma.
What interventions are being tested in trial NCT00025220?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Thalidomide (DRUG).
Who is sponsoring clinical trial NCT00025220?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025220 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uterine Corpus Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase II Clinical Trial Evaluating the Combination of Olaparib and Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
COMPLETED · Phase 2
Explore more on PlainTrial
Uterine Corpus Leiomyosarcoma
All registered trials for this condition
Recurrent Uterine Corpus Sarcoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.